To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After donating $176 million in ...
Stéphane Bancel, CEO, reported third quarter revenue of $1 billion, driven by sales of fully approved vaccines including Spikevax, mNEXSPIKE, and mRESVIA, and announced a net loss of $200 million for ...
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area. “We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results